Moderna commits 100 million COVID-19 vaccine doses to the US
pharmafile | August 12, 2020 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | COVID-19, Moderna, US, Vaccine, pharma
Moderna continues to rise to meet the demands of the pandemic, signing a new deal with the US Government to supply 100 million doses of its messenger RNA (mRNA) vaccine candidate for the prevention of COVID-19.
The agreement commits up to $1.525 billion to cover the manufacture and delivery of candidate mRNA-1273, and includes “incentive payments” to encourage that the vaccine is delivered as quickly as possible.
This follows the previous agreement of up to $955 million signed by Moderna with the Biomedical Advanced Research and Development Authority (BARDA), meaning the US Government has now committed $2.48 billion in total to the research and delivery of the vaccine candidate under its Operation Warp Speed.
“For Operation Warp Speed, we are assembling a broad portfolio of vaccines to increase the odds that we will have at least one safe, effective vaccine as soon as the end of this year,” commented Alex Azar, US Secretary of Health and Human Services. “With this latest investment, we will have supported the vaccine candidate developed by Moderna in partnership with the NIH all the way from early development through clinical trials and now manufacturing, with the potential to bring millions of safe and effective doses to the American people.”
Under the terms of the deal, the US Government will also have the option to reserve a further 400 million doses of the vaccine.
“We appreciate the confidence of the US Government in our mRNA vaccine platform and the continued support,” remarked Stéphane Bancel, Moderna’s Chief Executive Officer. “We are advancing the clinical development of mRNA-1273 with the ongoing Phase 3 study being conducted in collaboration with NIAID and BARDA. In parallel, we are scaling up our manufacturing capability with our strategic partners, Lonza, Catalent and Rovi, to address this global health emergency with a safe and effective vaccine.”
Matt Fellows
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
